Millipore introduced its Viresolve Pro+ virus-filtration product at the JP Morgan Healthcare Conference in San Francisco, California.
Biological drug products such as monoclonal antibodies and therapeutic proteins are manufactured using biological source material and production processes that can become contaminated with viruses.
As a result, biopharmaceutical manufacturers are required to incorporate sufficient virus clearance steps into their manufacturing processes to ensure their products are free of virus contamination.
Millipore's virus safety products provide customers with effective and robust virus filtration, from process development to full-scale biopharmaceutical production.
Viresolve Pro+ Solution strengthens Millipore's offerings by providing a robust parvovirus clearance that works effectively at higher titer feedstreams.
Parvoviruses are some of the smallest viruses found in nature, which makes them difficult to remove in the manufacturing process.
Viresolve Pro+ is available in a disposable flow path and increases the overall capacity and productivity of biopharmaceutical manufacturers' virus-removal operations.
It is designed to fit both monoclonal antibody and therapeutic protein processes.
It also includes a proprietary binary gas integrity test (BGT) to detect the presence of oversized pores or defects that can compromise a filter's retention capability and cause contamination in the end product - providing a critical quality-control safeguard for the end user.
